← Back to search
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
NEW YORK, NY, 10022
UnclaimedClaim this profile (free)
Prime contracting experience
5 records from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Prime | Department of Health and Human Services Centers for Disease Control and Prevention | TUBERCULOSIS TRIALS AND CONSORTIUM SERVICES | — | $3,225,561 | Sep 21, 2026 | Jan 1, 2021 – Dec 31, 2026 |
| Prime | Department of Health and Human Services National Institutes of Health | FRAMESHIFT PEPTIDE VACCINE FOR THE PREVENTION LYNCH SYNDROME-ASSOCIATED GASTROINTESTINAL CANCER HHSN2612015000391 TORFP: 2018-E12 POP: 9/17/2018 TO 3/16/2021 | HHSN261201500039IUSAspending | $891,984 | Aug 22, 2023 | Sep 13, 2018 – Aug 16, 2023 |
| Prime | Department of Health and Human Services National Institutes of Health | IGF::OT::IGF ANTI FUSOBACTERIUM NUCLEATUM VACCINE FOR COLORECTAL CANCER IMMUNOPREVENTION | HHSN261201500039IUSAspending | $1,246,582 | May 22, 2023 | Sep 8, 2016 – Sep 7, 2022 |
| Prime | Department of Health and Human Services Food and Drug Administration | BAA-19-00123 - PMWP#132 - DEVELOPMENT OF RABBIT ANIMAL MODELS OF VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA PRODUCED BY CARBAPENEM-RESISTANT PSEUDOMONAS AERUGINOSA AND ACINETOBACTER BAUMANNII | — | $994,896 | Nov 29, 2022 | Sep 14, 2020 – Jun 30, 2023 |
| Prime | Department of Health and Human Services National Institutes of Health | IGF::OT::IGF TESTING OF COMBINATION IMMUNO AND CHEMOPREVENTION STRATEGIES FOR LYNCH SYNDROME GASTROINTESTINAL CANCER | HHSN261201500039IUSAspending | $828,445 | Sep 14, 2022 | Sep 24, 2015 – Sep 23, 2019 |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.
Subcontracting experience
11 records from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Subcontractor | Department of Health and Human Services | THE CARDIOVASCULAR CENTER, IN COLLABORATION WITH THE COORDINATING CENTER, SHALL:
1. COMPLETE ORDERLY, SECURE, AND EFFICIENT TRANSITION OF ALL SHS ACTIVITIES, DATA, DOCUMENTS AND OTHER MATERIALS ACQUIRED THROUGH FEDERAL GRANTS AND COOPERATIVE AGREEMENTS, FROM 1989 TO THE CONTRACT AWARD DATE, IN COLLABORATION WITH THE COORDINATING CENTER (TASK AREA A)
DURING THE TRANSITION PHASE-IN PROCESS THE CARDIOVASCULAR CENTER WILL WORK WITH THE COORDINATING CENTER AT OUHSC AND TRIBAL PARTNERS TO:
A. FACILITATE AN ORDERLY TRANSITION, INCLUDING:
1. OBTAINING IRB APPROVAL FOR PHASE VII – THE CORNELL IRB HAS RULED THAT SINCE THERE IS NO CORNELL CONTACT WITH PARTICIPANTS AND NO ACCESS TO IDENTIFIERS, SHS PHASE VII IS EXEMPT FROM THEIR REVIEW.
2. SHIFT SALARY FOR CORNELL INVESTIGATORS TO THE CONTRACT.
3. COMPLETE ACTIVATION OF THE DATA CORE FOR SECURE STORAGE AND ACCESS FOR SHS/SHFS DATA AT CORNELL, AND ARRANGE APPROPRIATE SECURE ACCESS FOR CORNELL AND NON-CORNELL INVESTIGATORS WITH APPROVED MANUSCRIPT OR PRESENTATION PROJECTS.
4. SUBMIT REQUIRED CORNELL IT SECURITY INFORMATION AS PER THE CONTRACT.
B. CONTINUE PERFORMANCE WITHOUT INTERRUPTION.
2. ATTEND MEETINGS OF THE SHS STEERING COMMITTEE, IN CONJUNCTION WITH COMMUNITY ADVISORY BOARD MEETINGS (TASK AREA A)
3. PARTICIPATE COLLABORATIVELY IN THE STEERING COMMITTEE AND OTHER APPROPRIATE STUDY COMMITTEES TO DEVELOP AND UPDATE AND REFINE A COORDINATED PLAN TO ACHIEVE THE STUDY OBJECTIVES. (TASK AREAS A AND D)
4. PROVIDE EXPERT REVIEW OF POTENTIAL CLINICAL EVENTS; AND CLASSIFICATION THEREOF. (TASK AREAS A AND D)
5. PARTICIPATE IN THE STUDY’S QUALITY CONTROL AND ASSURANCE ACTIVITIES RELATED TO MORBIDITY AND MORTALITY REVIEW. (TASK AREAS A AND D)
6. COLLABORATE ON THE MANAGEMENT OF AN IMAGE REPOSITORY OF PREVIOUSLY COLLECTED AND ANY FUTURE IMAGES. (TASK AREAS A AND D)
7. ATTEND MEETINGS OF AN NHLBI-APPOINTED OBSERVATIONAL STUDIES MONITORING BOARD (OSMB) AS DIRECTED BY THE NHLBI PROJECT OFFICE. (TASK AREAS A AND D)
8. MENTOR AND PROVIDE FORMAL AND/OR INFORMAL TRAINING OPPORTUNITIES FOR JUNIOR AND EARLY CAREER INVESTIGATORS, FELLOWS, AND STUDENTS. (TASK AREAS A AND D)
9. COLLABORATE ON PUBLICATIONS AND PRESENTATIONS (TASK AREA A)
10. PREPARE AND SUBMIT TECHNICAL AND FINANCIAL REPORTS AND MONTHLY INVOICES. (TASK AREAS A, B, C, D, AND E) RS20180873-03 Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541715 Parent award performance state: OK Parent award description: STRONG HEART STUDY (SHS)- COORDINATING CENTER (CC)- TASK ORDER 001 View parent award on USAspending | 75N92019D00027USAspending | $141,703 | Jul 19, 2026 | — – — |
| Subcontractor | Department of Health and Human Services | THE CONTINUUM OF CARE IN HOSPITALIZED PATIENTS WITH OPIOID USE DISORDER AND INFECTIOUS COMPLICATIONS OF DRUG USE (CHOICE). 21890- KB 8933 Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541990 Parent award performance state: MD Parent award description: CHOICE PLUS STUDY View parent award on USAspending | — | $212,309 | Jul 7, 2025 | — – — |
| Subcontractor | Department of Health and Human Services | THE CARDIOVASCULAR CENTER, IN COLLABORATION WITH THE COORDINATING CENTER, SHALL:
1. COMPLETE ORDERLY, SECURE, AND EFFICIENT TRANSITION OF ALL SHS ACTIVITIES, DATA, DOCUMENTS AND OTHER MATERIALS ACQUIRED THROUGH FEDERAL GRANTS AND COOPERATIVE AGREEMENTS, FROM 1989 TO THE CONTRACT AWARD DATE, IN COLLABORATION WITH THE COORDINATING CENTER (TASK AREA A)
DURING THE TRANSITION PHASE-IN PROCESS THE CARDIOVASCULAR CENTER WILL WORK WITH THE COORDINATING CENTER AT OUHSC AND TRIBAL PARTNERS TO:
A. FACILITATE AN ORDERLY TRANSITION, INCLUDING:
1. OBTAINING IRB APPROVAL FOR PHASE VII – THE CORNELL IRB HAS RULED THAT SINCE THERE IS NO CORNELL CONTACT WITH PARTICIPANTS AND NO ACCESS TO IDENTIFIERS, SHS PHASE VII IS EXEMPT FROM THEIR REVIEW.
2. SHIFT SALARY FOR CORNELL INVESTIGATORS TO THE CONTRACT.
3. COMPLETE ACTIVATION OF THE DATA CORE FOR SECURE STORAGE AND ACCESS FOR SHS/SHFS DATA AT CORNELL, AND ARRANGE APPROPRIATE SECURE ACCESS FOR CORNELL AND NON-CORNELL INVESTIGATORS WITH APPROVED MANUSCRIPT OR PRESENTATION PROJECTS.
4. SUBMIT REQUIRED CORNELL IT SECURITY INFORMATION AS PER THE CONTRACT.
B. CONTINUE PERFORMANCE WITHOUT INTERRUPTION.
2. ATTEND MEETINGS OF THE SHS STEERING COMMITTEE, IN CONJUNCTION WITH COMMUNITY ADVISORY BOARD MEETINGS (TASK AREA A)
3. PARTICIPATE COLLABORATIVELY IN THE STEERING COMMITTEE AND OTHER APPROPRIATE STUDY COMMITTEES TO DEVELOP AND UPDATE AND REFINE A COORDINATED PLAN TO ACHIEVE THE STUDY OBJECTIVES. (TASK AREAS A AND D)
4. PROVIDE EXPERT REVIEW OF POTENTIAL CLINICAL EVENTS; AND CLASSIFICATION THEREOF. (TASK AREAS A AND D)
5. PARTICIPATE IN THE STUDY’S QUALITY CONTROL AND ASSURANCE ACTIVITIES RELATED TO MORBIDITY AND MORTALITY REVIEW. (TASK AREAS A AND D)
6. COLLABORATE ON THE MANAGEMENT OF AN IMAGE REPOSITORY OF PREVIOUSLY COLLECTED AND ANY FUTURE IMAGES. (TASK AREAS A AND D)
7. ATTEND MEETINGS OF AN NHLBI-APPOINTED OBSERVATIONAL STUDIES MONITORING BOARD (OSMB) AS DIRECTED BY THE NHLBI PROJECT OFFICE. (TASK AREAS A AND D)
8. MENTOR AND PROVIDE FORMAL AND/OR INFORMAL TRAINING OPPORTUNITIES FOR JUNIOR AND EARLY CAREER INVESTIGATORS, FELLOWS, AND STUDENTS. (TASK AREAS A AND D)
9. COLLABORATE ON PUBLICATIONS AND PRESENTATIONS (TASK AREA A)
10. PREPARE AND SUBMIT TECHNICAL AND FINANCIAL REPORTS AND MONTHLY INVOICES. (TASK AREAS A, B, C, D, AND E) RS20180873-03 Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541715 Parent award performance state: OK Parent award description: STRONG HEART STUDY (SHS)- COORDINATING CENTER (CC)- TASK ORDER 001 View parent award on USAspending | 75N92019D00027USAspending | $155,361 | Apr 28, 2025 | — – — |
| Subcontractor | Department of Health and Human Services | IN THE PRESENT PROJECT, THE SANTAMBROGIO'S LABORATORY WILL PERFORM MHC ELUTION AND IDENTIFICATION OF THE ELUTED
PEPTIDES TOWARD THE DISCOVERY OF NOVEL EPITOPES ASSOCIATED WITH HUMAN INFLAMMATORY AND AUTOIMMUNE DISEASES.
EXPERIMENTS WILL BE PERFORMED BY TWO VERY TALENTED JUNIOR FACULTY WITH EXTENSIVE EXPERIENCE IN MHC
IMMUNOAFFINITY ELUTION AND CHARACTERIZATION OF THE MHC LIGANDOME.
ALL EXPERIMENTS WILL BE PERFORMED IN A COLLABORATIVE FASHION WITH THE LABORATORIES INCLUDED IN THIS APPLICATION. SUB00000582 Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541714 Parent award performance state: MA Parent award description: CD4 AND CD8 T CELL EPITOPES RECOGNIZED IN AUTOIMMUNE AND AUTOINFLAMMATORY DISEASES View parent award on USAspending | — | $231,968 | Feb 18, 2025 | — – — |
| Subcontractor | Department of Health and Human Services | THE CARDIOVASCULAR CENTER, IN COLLABORATION WITH THE COORDINATING CENTER, SHALL:
1. COMPLETE ORDERLY, SECURE, AND EFFICIENT TRANSITION OF ALL SHS ACTIVITIES, DATA, DOCUMENTS AND OTHER MATERIALS ACQUIRED THROUGH FEDERAL GRANTS AND COOPERATIVE AGREEMENTS, FROM 1989 TO THE CONTRACT AWARD DATE, IN COLLABORATION WITH THE COORDINATING CENTER (TASK AREA A)
DURING THE TRANSITION PHASE-IN PROCESS THE CARDIOVASCULAR CENTER WILL WORK WITH THE COORDINATING CENTER AT OUHSC AND TRIBAL PARTNERS TO:
A. FACILITATE AN ORDERLY TRANSITION, INCLUDING:
1. OBTAINING IRB APPROVAL FOR PHASE VII €€Œ THE CORNELL IRB HAS RULED THAT SINCE THERE IS NO CORNELL CONTACT WITH PARTICIPANTS AND NO ACCESS TO IDENTIFIERS, SHS PHASE VII IS EXEMPT FROM THEIR REVIEW.
2. SHIFT SALARY FOR CORNELL INVESTIGATORS TO THE CONTRACT.
3. COMPLETE ACTIVATION OF THE DATA CORE FOR SECURE STORAGE AND ACCESS FOR SHS/SHFS DATA AT CORNELL, AND ARRANGE APPROPRIATE SECURE ACCESS FOR CORNELL AND NON-CORNELL INVESTIGATORS WITH APPROVED MANUSCRIPT OR PRESENTATION PROJECTS.
4. SUBMIT REQUIRED CORNELL IT SECURITY INFORMATION AS PER THE CONTRACT.
B. CONTINUE PERFORMANCE WITHOUT INTERRUPTION.
2. ATTEND MEETINGS OF THE SHS STEERING COMMITTEE, IN CONJUNCTION WITH COMMUNITY ADVISORY BOARD MEETINGS (TASK AREA A)
3. PARTICIPATE COLLABORATIVELY IN THE STEERING COMMITTEE AND OTHER APPROPRIATE STUDY COMMITTEES TO DEVELOP AND UPDATE AND REFINE A COORDINATED PLAN TO ACHIEVE THE STUDY OBJECTIVES. (TASK AREAS A AND D)
4. PROVIDE EXPERT REVIEW OF POTENTIAL CLINICAL EVENTS; AND CLASSIFICATION THEREOF. (TASK AREAS A AND D)
5. PARTICIPATE IN THE STUDY€„¢S QUALITY CONTROL AND ASSURANCE ACTIVITIES RELATED TO MORBIDITY AND MORTALITY REVIEW. (TASK AREAS A AND D)
6. COLLABORATE ON THE MANAGEMENT OF AN IMAGE REPOSITORY OF PREVIOUSLY COLLECTED AND ANY FUTURE IMAGES. (TASK AREAS A AND D)
7. ATTEND MEETINGS OF AN NHLBI-APPOINTED OBSERVATIONAL STUDIES MONITORING BOARD (OSMB) AS DIRECTED BY THE NHLBI PROJECT OFFICE. (TASK AREAS A AND D)
8. MENTOR AND PROVIDE FORMAL AND/OR INFORMAL TRAINING OPPORTUNITIES FOR JUNIOR AND EARLY CAREER INVESTIGATORS, FELLOWS, AND STUDENTS. (TASK AREAS A AND D)
9. COLLABORATE ON PUBLICATIONS AND PRESENTATIONS (TASK AREA A)
10. PREPARE AND SUBMIT TECHNICAL AND FINANCIAL REPORTS AND MONTHLY INVOICES. (TASK AREAS A, B, C, D, AND E) RS20180873-03 Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541715 Parent award performance state: OK Parent award description: STRONG HEART STUDY (SHS)- COORDINATING CENTER (CC)- TASK ORDER 001 View parent award on USAspending | 75N92019D00027USAspending | $182,700 | Jun 5, 2024 | — – — |
| Subcontractor | Department of Health and Human Services | THE CARDIOVASCULAR CENTER, IN COLLABORATION WITH THE COORDINATING CENTER, SHALL:
1. COMPLETE ORDERLY, SECURE, AND EFFICIENT TRANSITION OF ALL SHS ACTIVITIES, DATA, DOCUMENTS AND OTHER
MATERIALS ACQUIRED THROUGH FEDERAL GRANTS AND COOPERATIVE AGREEMENTS, FROM 1989 TO THE CONTRACT
AWARD DATE, IN COLLABORATION WITH THE COORDINATING CENTER (TASK AREA A)
DURING THE TRANSITION PHASE-IN PROCESS THE CARDIOVASCULAR CENTER WILL WORK WITH THE COORDINATING CENTER
AT OUHSC AND TRIBAL PARTNERS TO:
A. FACILITATE AN ORDERLY TRANSITION, INCLUDING:
1. OBTAINING IRB APPROVAL FOR PHASE VII €€Œ THE CORNELL IRB HAS RULED THAT SINCE THERE IS NO
CORNELL CONTACT WITH PARTICIPANTS AND NO ACCESS TO IDENTIFIERS, SHS PHASE VII IS EXEMPT FROM
THEIR REVIEW.
2. SHIFT SALARY FOR CORNELL INVESTIGATORS TO THE CONTRACT.
3. COMPLETE ACTIVATION OF THE DATA CORE FOR SECURE STORAGE AND ACCESS FOR SHS/SHFS DATA AT
CORNELL, AND ARRANGE APPROPRIATE SECURE ACCESS FOR CORNELL AND NON-CORNELL INVESTIGATORS WITH
APPROVED MANUSCRIPT OR PRESENTATION PROJECTS.
4. SUBMIT REQUIRED CORNELL IT SECURITY INFORMATION AS PER THE CONTRACT.
B. CONTINUE PERFORMANCE WITHOUT INTERRUPTION.
2. ATTEND MEETINGS OF THE SHS STEERING COMMITTEE, IN CONJUNCTION WITH COMMUNITY ADVISORY BOARD MEETINGS
(TASK AREA A)
3. PARTICIPATE COLLABORATIVELY IN THE STEERING COMMITTEE AND OTHER APPROPRIATE STUDY COMMITTEES TO DEVELOP AND
UPDATE AND REFINE A COORDINATED PLAN TO ACHIEVE THE STUDY OBJECTIVES. (TASK AREAS A AND D)
4. PROVIDE EXPERT REVIEW OF POTENTIAL CLINICAL EVENTS; AND CLASSIFICATION THEREOF. (TASK AREAS A AND D)
5. PARTICIPATE IN THE STUDY€„¢S QUALITY CONTROL AND ASSURANCE ACTIVITIES RELATED TO MORBIDITY AND MORTALITY REVIEW.
(TASK AREAS A AND D)
6. COLLABORATE ON THE MANAGEMENT OF AN IMAGE REPOSITORY OF PREVIOUSLY COLLECTED AND ANY FUTURE IMAGES. (TASK
AREAS A AND D)
7. ATTEND MEETINGS OF AN NHLBI-APPOINTED OBSERVATIONAL STUDIES MONITORING BOARD (OSMB) AS DIRECTED BY THE
NHLBI PROJECT OFFICE. (TASK AREAS A AND D)
8. MENTOR AND PROVIDE FORMAL AND/OR INFORMAL TRAINING OPPORTUNITIES FOR JUNIOR AND EARLY CAREER INVESTIGATORS,
FELLOWS, AND STUDENTS. (TASK AREAS A AND D)
9. COLLABORATE ON PUBLICATIONS AND PRESENTATIONS (TASK AREA A)
10. PREPARE AND SUBMIT TECHNICAL AND FINANCIAL REPORTS AND MONTHLY INVOICES. (TASK AREAS A, B, C, D, AND E) RS20180873-03 Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541715 Parent award performance state: OK Parent award description: STRONG HEART STUDY (SHS)- COORDINATING CENTER (CC)- TASK ORDER 001 View parent award on USAspending | 75N92019D00027USAspending | $162,145 | May 12, 2023 | — – — |
| Subcontractor | Department of Health and Human Services | STATEMENT OF WORK
SARS-COV-2 B CELL EPITOPE MAPPING SUPPLEMENT (WILSON)
SUBCONTRACT TO THE SUPPLEMENT FOR:
NIAID CONTRACT 75N93019C00062 (FREEMONT, PI, PD)
B CELL MEDIATED MECHANISMS OF PROTECTION FROM SARS-COV-2
PATRICK C. WILSON, SUBCONTRACT PI
WEILL COLLEGE OF MEDICINE OF CORNELL UNIVERSITY
E-MAIL: PCW4001@MED.CORNELL.EDU
€ƒ
STATEMENT OF WORK
CORONAVIRUSES ARE ENVELOPED NON-SEGMENTED POSITIVE-SENSE RNA VIRUSES BELONGING TO THE FAMILY CORONAVIRIDAE AND CIRCULATE BROADLY AMONGST AND BETWEEN HUMANS AND OTHER MAMMALS. OVER THE PAST TWO DECADES, TWO BETACORONAVIRUSES, SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS (SARS-COV) AND MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS (MERS-COV), WERE RESPONSIBLE FOR OVER 10,000 CASES OF INFECTION. THE MORTALITY RATE OF SARS-COV WAS 10% WITH 29 COUNTRIES AFFECTED, AND THE MORTALITY RATE OF MERS WAS 35% WITH 27 COUNTRIES AFFECTED GLOBALLY. IN DECEMBER OF 2019, A NOVEL CORONAVIRUS (2019-NCOV) WAS DISCOVERED THROUGH DEEP SEQUENCING ANALYSIS AFTER A SERIES OF PNEUMONIA CASES WERE REPORTED IN WUHAN, HUBEI, CHINA WITH UNKNOWN VIRAL ORIGIN. SEVERAL INDEPENDENT STUDIES HAVE SINCE CONFIRMED THAT THE NOVEL VIRUS ORIGINATED FROM EXPOSURES IN A WUHAN SEAFOOD MARKET. BY ONLY MARCH 16, 2020, 2019-NCOV CAUSED A PANDEMIC SPANNING MOST COUNTRIES ON EARTH WITH A REPORTED 167,000 PEOPLE INFECTED WORLDWIDE, AND ALMOST 7000 CONFIRMED DEATHS. CASE AND MORTALITY RATES ARE CONTINUING TO RISE AND THE LACK OF ADEQUATE TESTING IN MAJOR POPULATION CENTERS PLUS CLEAR EVIDENCE OF COMMUNITY TRANSMISSIONS SUGGESTS THAT THE NUMBER OF INFECTED IS LIKELY SIGNIFICANTLY GREATER. MOREOVER, AS THE VIRUS CONTINUES TO SPREAD, ITS HIGH MUTATION RATE INTRODUCES THE THREAT OF INFECTIONS WITH NEW VARIANTS WHICH COULD HAVE ALTERED SEVERITY AND TRANSMISSIBILITY. THESE OCCURRENCES NECESSITATE THE URGENCY OF NOVEL PROPHYLACTIC, THERAPEUTIC, AND DIAGNOSTIC MEASURES TO HELP PREVENT THE SPREAD OF NCOV-2019, WHICH POSES ONE OF THE GREATEST GLOBAL HEALTH THREATS IN MODERN HISTORY.
MONOCLONAL ANTIBODIES (MAB) ARE MONOVALENT PROTEINS EXPRESSED BY B CELLS THAT CAN SPECIFICALLY TARGET 3-DIMENSIONAL VIRAL EPITOPES, LEADING TO POTENT VIRAL NEUTRALIZATION. MABS HAVE REVOLUTIONIZED MODERN MEDICINE BY PROVIDING PRECISION MEDICINE AGAINST MANY DISEASES, WITH OVER 70 MAB-BASED DRUGS APPROVED BY THE FDA. THE ISOLATION OF HUMAN MABS SPECIFIC FOR HIGHLY IMMUNOGENIC NCOV-2019 PROTEINS CAN BE RAPIDLY USED AS THERAPEUTIC AGENTS, FOR THE PRODUCTION OF HIGH SENSITIVITY AND HIGH SPECIFICITY DIAGNOSTIC REAGENTS, AND FOR TEMPLATING THE GENERATION OF VACCINES THAT CAN PROTECT AGAINST NCOV-2019. OUR LABORATORY IS HIGHLY SPECIALIZED IN THE RAPID GENERATION OF NEUTRALIZING MABS FROM HUMAN B CELLS. WE AIM TO APPLY THIS EXPERTISE TO GENERATE HUMAN NCOV-2019-SPECIFIC MABS, WHICH HAVE THE POTENTIAL TO RAPIDLY ALLEVIATE THE GLOBAL HEALTH BURDEN IMPOSED BY NCOV-2019 THROUGH THREE CRITICAL MEASURES: PROPHYLACTIC, THERAPEUTIC, AND DIAGNOSTIC. BY INVESTIGATING THE HUMAN ANTIBODY RESPONSE TO NCOV-2019, WE WILL GAIN IMPORTANT INSIGHT INTO THE IMMUNOGENICITY AND IMMUNODOMINANCE OF NCOV-2019 VIRAL PROTEINS, WHICH WILL IN TURN INFORM WHICH VIRAL TARGETS WILL BE MOST IMPORTANT TO PURSUE WITH THERAPEUTICS AND VACCINES.
THE SPECIFIC OBJECTIVES OF OUR PROPOSED SUPPLEMENT ARE AS FOLLOWS:
A) GENERATE PANELS OF HUMAN MABS AGAINST SARS-COV-2 ANTIGENS. COVID-19 PATIENT BLOOD WILL BE OBTAINED FROM SEVERAL SOURCES INCLUDING VERIFIED INFECTED SAMPLES FROM TOKYO THROUGH COLLABORATOR YOSHI KAWAOKA, THROUGH THE UNIVERSITY OF CHICAGO OR OTHER HOSPITALS FROM COVID-19 ADMITTED PATIENTS, OR THROUGH OTHER COLLABORATING LABS. HUMAN MABS AGAINST SARS-COV-2 SPIKE PROTEIN, SPIKE RBD AND ORF7 FROM DAVED FREEMONT€„¢S LABORATORY, VERSIONS OF THE SPIKE PROTEIN AND RBD FROM FLORIAN KRAMMERS LABORATORY, PLUS NSP3, NSP5, NSP9, NSP10, NSP15, NSP16, AND N PROTEIN FROM ANDRJEZ JOACHIMIAC€„¢S LABORATORY, OR TO UNBIASED OTHER EPITOPES TARGETED BY ACTIVATED B CELLS AND PLASMABLASTS WILL BE WU-23-0276 Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541713 Parent award performance state: MO Parent award description: B CELL EPITOPE DISCOVERY AND MECHANISMS OF ANTIBODY PROTECTION View parent award on USAspending | — | $330,349 | Dec 29, 2022 | — – — |
| Subcontractor | Department of Health and Human Services | TRENDS IN OWNERSHIP STRUCTURES OF U.S. NURSING HOMES AND EFFECT ON QUALITY OF CARE STUDY 106314 · Prime awardUSAspending | — | $90,721 | Oct 19, 2022 | — – — |
| Subcontractor | Department of Health and Human Services | THE CARDIOVASCULAR CENTER, IN COLLABORATION WITH THE COORDINATING CENTER, SHALL:
1. COMPLETE ORDERLY, SECURE, AND EFFICIENT TRANSITION OF ALL SHS ACTIVITIES, DATA, DOCUMENTS AND OTHER
MATERIALS ACQUIRED THROUGH FEDERAL GRANTS AND COOPERATIVE AGREEMENTS, FROM 1989 TO THE CONTRACT
AWARD DATE, IN COLLABORATION WITH THE COORDINATING CENTER (TASK AREA A)
DURING THE TRANSITION PHASE-IN PROCESS THE CARDIOVASCULAR CENTER WILL WORK WITH THE COORDINATING CENTER
AT OUHSC AND TRIBAL PARTNERS TO:
A. FACILITATE AN ORDERLY TRANSITION, INCLUDING:
1. OBTAINING IRB APPROVAL FOR PHASE VII €€Œ THE CORNELL IRB HAS RULED THAT SINCE THERE IS NO
CORNELL CONTACT WITH PARTICIPANTS AND NO ACCESS TO IDENTIFIERS, SHS PHASE VII IS EXEMPT FROM
THEIR REVIEW.
2. SHIFT SALARY FOR CORNELL INVESTIGATORS TO THE CONTRACT.
3. COMPLETE ACTIVATION OF THE DATA CORE FOR SECURE STORAGE AND ACCESS FOR SHS/SHFS DATA AT
CORNELL, AND ARRANGE APPROPRIATE SECURE ACCESS FOR CORNELL AND NON-CORNELL INVESTIGATORS WITH
APPROVED MANUSCRIPT OR PRESENTATION PROJECTS.
4. SUBMIT REQUIRED CORNELL IT SECURITY INFORMATION AS PER THE CONTRACT.
B. CONTINUE PERFORMANCE WITHOUT INTERRUPTION.
2. ATTEND MEETINGS OF THE SHS STEERING COMMITTEE, IN CONJUNCTION WITH COMMUNITY ADVISORY BOARD MEETINGS
(TASK AREA A)
3. PARTICIPATE COLLABORATIVELY IN THE STEERING COMMITTEE AND OTHER APPROPRIATE STUDY COMMITTEES TO DEVELOP AND
UPDATE AND REFINE A COORDINATED PLAN TO ACHIEVE THE STUDY OBJECTIVES. (TASK AREAS A AND D)
4. PROVIDE EXPERT REVIEW OF POTENTIAL CLINICAL EVENTS; AND CLASSIFICATION THEREOF. (TASK AREAS A AND D)
5. PARTICIPATE IN THE STUDY€„¢S QUALITY CONTROL AND ASSURANCE ACTIVITIES RELATED TO MORBIDITY AND MORTALITY REVIEW.
(TASK AREAS A AND D)
6. COLLABORATE ON THE MANAGEMENT OF AN IMAGE REPOSITORY OF PREVIOUSLY COLLECTED AND ANY FUTURE IMAGES. (TASK
AREAS A AND D)
7. ATTEND MEETINGS OF AN NHLBI-APPOINTED OBSERVATIONAL STUDIES MONITORING BOARD (OSMB) AS DIRECTED BY THE
NHLBI PROJECT OFFICE. (TASK AREAS A AND D)
8. MENTOR AND PROVIDE FORMAL AND/OR INFORMAL TRAINING OPPORTUNITIES FOR JUNIOR AND EARLY CAREER INVESTIGATORS,
FELLOWS, AND STUDENTS. (TASK AREAS A AND D)
9. COLLABORATE ON PUBLICATIONS AND PRESENTATIONS (TASK AREA A)
10. PREPARE AND SUBMIT TECHNICAL AND FINANCIAL REPORTS AND MONTHLY INVOICES. (TASK AREAS A, B, C, D, AND E) RS20180873-03A3 Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541715 Parent award performance state: OK Parent award description: STRONG HEART STUDY (SHS)- COORDINATING CENTER (CC)- TASK ORDER 001 View parent award on USAspending | 75N92019D00027USAspending | $158,732 | Jun 1, 2022 | — – — |
| Subcontractor | Department of Health and Human Services | BASE: 0258-A504-4609
OPTION 1: 0258-B504-4609
OPTION 2: 0258-C504-4609
OPTION 3: 0258-D504-4609
OPTION 4: IF300302118-940002
OPTION 5: IF300302188-940002
RESEARCH PROJECT 3: ANTIBODY RESPONSES TO INFLUENZA VIRUS VACCINATION AND INFECTION.
AIM 3. COMPARING MEMORY B CELL DIFFERENTIATION AND ADAPTATION TO COVID-19 AND INFLUENZA IN COHORTS OF VARIED AGE AND DEGREE OF OBESITY.
UNDERSTANDING THE COMPOSITION AND SPECIFICITY OF MEMORY B CELL SUBSETS AGAINST NEUTRALIZING VIRAL EPITOPES IS CRITICAL FOR DETERMINING IMMUNE CORRELATES OF PROTECTION FROM SARS-COV-2 OR INFLUENZA INFECTION AND TO PREPARE FOR POTENTIAL FUTURE PANDEMICS. WE PROPOSE TO USE HIGH-THROUGHPUT APPROACHES TO CHARACTERIZE THE DIFFERENTIATION OF B MEMORY CELLS AND ADAPTATION TO INFLUENZA AND SARS-COV-2 ANTIGENS IN REPRESENTATIVE SUBSETS OF SUBJECTS OF VARIED AGED AND DEGREES OF OBESITY. LISTED FOLLOWING ARE THE AIMS/OBJECTIVES OF THIS PROJECT:
A. ANALYSIS OF MEMORY B CELL DIFFERENTIATION: WE WILL UTILIZE DISTINCT BARCODED SARS-COV-2 ANTIGEN BAITS TO ISOLATE THOUSANDS OF B CELLS IN MULTIPLE FUNCTIONAL SUBSETS SPECIFIC TO THE SPIKE, NUCLEOPROTEIN (NP), AND OPEN READING FRAME (ORF) PROTEINS 7A AND 8 AND TO INFLUENZA HA, NA AND NP FROM EACH SUBJECT.
B. ANALYSIS OF MEMORY B CELL SPECIFICITY: ANTIBODY GENE SEQUENCES FROM DROP-SEQ WILL BE USED TO EXPRESS PANELS OF SARS-COV-2 AND INFLUENZAS HA AND NA MONOCLONAL ANTIBODIES.
C. AN IMPORTANT COMPONENT OF THIS PROJECT IS PANDEMIC PREPAREDNESS: THE USE OF THE HIGH-THROUGHPUT TECHNOLOGIES TO GENERATE MONOCLONAL ANTIBODIES FROM ARISING PANDEMIC OR PANDEMIC-POTENTIAL PATHOGENS (I.E., INFLUENZA STRAINS OR CORONAVIRUSES) WILL ALLOW RAPID IDENTIFICATION OF PROTECTIVE EPITOPES AND THE PRODUCTION OF PROTECTIVE HUMAN ANTIBODIES THAT COULD BE USED THERAPEUTICALLY OR FOR DIAGNOSTIC PURPOSES. 0258-A504-4609 Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541715 Parent award performance state: NY Parent award description: MSSM CEIRR - THIS CONTRACT WILL SUPPORT THE NIAID CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND RESPONSE. View parent award on USAspending | — | $901,391 | Mar 2, 2022 | — – — |
| Subcontractor | Department of Health and Human Services | OPTION 1: 0258-A428-4609
OPTION 2: 0258-A443-4609
OPTION 3: 0258-A457-4609
OPTION 4: 0258-B457-4609
OPTION 5: 0258-C457-4609
OPTION 6: IF300302155-940002
THE PATRICK WILSON LAB TEAM AT WEILL CORNELL MEDICINE WILL SERVE THREE PRIMARY ROLES FOR THE OVERALL CIVIC TEAM. FIRST, WE WILL PROVIDE HUMAN MONOCLONAL ANTIBODIES TO KEY EPITOPES FROM OUR EXTENSIVE EXISTING COLLECTION THAT WILL BE OF VALUE IN TEMPLATING AND EVALUATING NOVEL VACCINE CANDIDATES AND FOR VACCINE DESIGN. SECONDLY, THE SPECIFICITY AND FUNCTIONAL CAPACITY OF ANTIBODIES INDUCED BY NOVEL VACCINE CANDIDATES IS A CENTRAL COMPONENT OF VACCINE DEVELOPMENT AND SO MAB PRODUCTION AND CHARACTERIZATION WILL ALSO BE A PRIMARY OBLIGATION AT THE WEILL CORNELL MEDICINE SITE. FINALLY, UNDERSTANDING THE B CELL RESPONSE UNDER-PINNING THE ANTIBODIES ACTIVATED WILL BE IMPORTANT FOR IMPROVING THE INFLUENZA VACCINE IN ORDER TO OVERCOME PREDILECTIONS OF OUR IMMUNE RESPONSE TO TARGET PARTICULAR IMMUNO-DOMINANT EPITOPES DUE TO POORLY UNDERSTOOD PHENOMENON SUCH AS IMMUNE IMPRINTING OR ORIGINAL-ANTIGENIC SIN. THESE ANALYSES WILL BE DONE IN CONJUNCTION WITH WORK FROM OTHER INVESTIGATORS IN THE VACCINE CENTER TO CHARACTERIZE ALL ASPECTS OF THE IMMUNE RESPONSE ELICITED SUCH AS T CELL RESPONSES, SEROLOGY, AND INNATE RESPONSES. THE COMBINED CHARACTERIZATION OF RESPONSES FIRST PRE-CLINICALLY IN MICE, FERRETS, AND GUINEA PIGS, AND LATER ON HUMAN BLOOD SAMPLES UPON CLINICAL TRIALS, WILL GUIDE THE ITERATIVE DESIGN OF NOVEL AND MORE EFFECTIVE INFLUENZA VACCINES.
OPTION 17A: 0258-A412-4609
THE PATRICK WILSON LAB TEAM AT WEILL CORNELL MEDICINE WILL WORK TO CHARACTERIZE B CELL RESPONSES AND TO CLONE AND EXPRESS ANTIBODIES TO SARS-COV-2. SPECIFIC ANTIBODY RESPONSES TO SARS-COV-1 HAVE BEEN ASSOCIATED WITH EFFECTIVE AND DESTRUCTIVE IMMUNE RESPONSES. NON-HUMAN PRIMATE MODELS OF SARS-COV-1 HAVE SHOWN THAT ANTI-SPIKE IGG RESPONSES WERE ASSOCIATED WITH MACROPHAGE-MEDIATED LUNG DESTRUCTION. IDENTIFYING VIRAL EPITOPES AND EFFECTIVE MONOCLONAL ANTIBODY RESPONSES WOULD THEREFORE SERVE TO GUIDE VACCINE DEVELOPMENT AND POTENTIAL ANTIBODY THERAPIES. WE WILL ISOLATE THE B CELLS FROM RECOVERED COVID-19 CONVALESCENT SERA DONORS. MONOCLONAL ANTIBODIES WILL BE MADE FROM THE MOST EFFECTIVE CONVALESCENT SERA DONORS, OR €œSUPER-RESPONDERS€Ͽ½ BASED ON CLINICAL RESPONSES IN THE SERUM TRANSFER RECIPIENTS. THESE ANTIBODIES WILL BE TESTED FOR BINDING, IN VITRO POTENCY AND EPITOPE BOUND. KEY CANDIDATE ANTIBODIES WILL BE TESTED FOR IN VIVO ACTIVITIES IN RELEVANT ANIMAL MODELS.
OPTION 17C: 0258-A436-4609
THE PATRICK WILSON LAB TEAM AT WEILL CORNELL MEDICINE WILL WORK TO CLONE AND EXPRESS ANTIBODIES TO SARS-COV-2 VARIANT STRAINS. WE WILL ISOLATE THE B CELLS FROM RECOVERED COVID-19 OR VACCINATED AGAINST SARS-COV-2. MONOCLONAL ANTIBODIES WILL BE MADE. THESE ANTIBODIES WILL BE TESTED FOR BINDING, IN VITRO POTENCY AND EPITOPE BOUND AGAINST SARS-COV-2 VARIANTS. KEY CANDIDATE ANTIBODIES WILL BE TESTED FOR IN VIVO ACTIVITIES IN RELEVANT ANIMAL MODELS.
OPTION 23E: IF300302080
WE PROPOSE THREE SPECIFIC AIMS TO CONTINUE THIS STUDY:
AIM 1: CHARACTERIZING THE ANTI-S2 B CELL RESPONSES AND ANTIBODIES IN SEVERE COVID-19 PATIENTS.
AIM 2: TEST THE HYPOTHESIS AND WORK TO DETERMINE THE MECHANISM AS TO WHY OC43 PRIMES NEUTRALIZING
SARS-COV-2 ANTIBODIES BUT SARS-COV-2 PRIME-BOOST ALONE DOES NOT.
AIM 3: CONTINUE MAB AND EPITOPE DISCOVERY EFFORTS FROM SEVERE ACUTE INFECTED PATIENT SAMPLES AS
THERE ARE OTHER CONSERVED EPITOPES BEING TARGETED.
OPTION 11J: IF300302178
HARNESSING B CELL MEMORY ELICITED BY CHIMERIC HEMAGGLUTININ VACCINATION TO ENABLE H5N1 CLADE 2.3.4.4B
PANDEMIC PREPAREDNESS 0258-A443-4609 Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541715 Parent award performance state: NY Parent award description: THIS CONTRACT WILL SUPPORT COMPONENT A OF THE COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) PROGRAM TO DESIGN AND EVALUATE INNOVATIVE INFLUENZA VACCINE APPROACHES, BASED ON PRINCIPLES OF INFLUENZA IMMUNITY, THAT ACHIEVE DURABLE, ROBUST View parent award on USAspending | — | $3,730,069 | Jan 13, 2022 | — – — |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.
Agencies supported
- Department of Health and Human ServicesGov-sourced
Government-sourced data comes from SAM.gov, SBA and USAspending.gov and is attributed to its source. Items marked company-reported were provided by the company and are verified by FedSub only where labeled. FedSub is a private company and is not affiliated with SBA, GSA/SAM.gov, or any government agency.